Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Endocr Pract. 2020 Dec;26(12):1416–1424. doi: 10.4158/EP-2020-0277

Table 4.

Factors Associated With Alterations of an Initially Positive PA Screening Test by MRA Therapy

Variable β SE (β) P Odds ratio 95% CI
Beta-blocker use −1.76 0.55 .001 0.17 0.06–0.50
PA −2.35 0.72 .001 0.10 0.02–0.39
MRA dose (mg/day) 0.03 0.01 .01 1.03 1.01–1.06

Abbreviations: CI = confidence interval; MRA = mineralocorticoid receptor antagonist; PA = primary aldosteronism; SE = standard error.